Advanced search
Publication Cover
Journal of Intellectual & Developmental Disability Volume 34, 2009 - Issue 3
Submit an article Journal homepage
188
Views
10
CrossRef citations to date
0
Altmetric
Case Report

Extrapyramidal symptoms and medication use in Mucopolysaccharidosis type IIIFootnote

Michel C. Tchan The Children's Hospital at Westmead, Sydney, AustraliaCorrespondence[email protected]
&
David Sillence The Children's Hospital at Westmead, Sydney, Australia
Pages 275-279 | Published online: 19 Sep 2009

References

  • Ausseil J., Loredo-Osti J. C., Verner A., Darmond-Zwaig C., Maire I., Poorthuis B., et al. Localisation of a gene for mucopolysaccharidosis IIIC to the pericentromeric region of chromosome 8. Journal of Medical Genetics 2004; 41: 941–945
  • Bax M. C. O., Colville G. A. Behaviour in mucopolysaccharide disorders. Archives of Disease in Childhood 1995; 73: 77–81
  • Cleary M. A., Wraith J. E. Management of mucopolysaccharidosis type III. Archives of Disease in Childhood 1993; 69: 403–406
  • Das K. B., Harris C., Smyth D. P. L., Cross J. H. Unusual side effects of lamotrigine therapy. Journal of Child Neurology 2003; 18: 479–480
  • Fraser J., Gason A. A., Wraith J. E., Delatycki M. B. Sleep disturbance in Sanfilippo syndrome: A parental questionnaire study. Archives of Disease in Childhood 2005; 90: 1239–1242
  • Fraser J., Wraith J. E., Delatycki M. B. Sleep disturbance in mucopolysaccharidosis type III (Sanfilippo syndrome): A survey of managing clinicians. Clinical Genetics 2002; 62: 418–421
  • Geddes J., Freemantle N., Harrison P., Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: Systematic overview and meta-regression analysis. British Medical Journal 2000; 321: 1371–1376
  • Jones M. Z., Alroy J., Rutledge J. C., Taylor J. W., Alvord E. C., Jr, Toone J., et al. Human mucopolysaccharidosis IIID: Clinical, biochemical, morphological and immunohistochemical characteristics. Journal of Neuropathology & Experimental Neurology 1997; 56: 1158–1167
  • Kushner S. A., Guze B. H. Treatment of psychomotor agitation and self-injurious behavior with estrogen and progesterone in a patient with Sanfilippo syndrome [Letter to the editor]. General Hospital Psychiatry 2005; 27: 298–300
  • McGlynn R., Dobrenis K., Walkley S. U. Differential subcellular localization of cholesterol, gangliosides, and glycosaminoglycans in murine models of mucopolysaccharide storage disorders. Journal of Comparative Neurology 2004; 480: 415–426
  • Meyer A., Kossow K., Gal A., Mühlhausen C., Ullrich K., Braulke T., et al. Scoring evaluation of the natural course of mucopolysaccharidosis type IIIA (Sanfilippo syndrome type A). Pediatrics 2007; 120: e1255–e1261
  • Miller M. A., Levsky M. E. Choreiform dyskinesia following isolated lamotrigine overdose. Journal of Child Neurology 2008; 23: 243
  • Mok A., Cao H., Hegele R. A. Genomic basis of mucopolysaccharidosis type IIID (MIM 252940) revealed by sequencing of GNS encoding N-acetylglucosamine-6-sulfatase. Genomics 2003; 81: 1–5
  • Nidiffer F. D., Kelly T. E. Developmental and degenerative patterns associated with cognitive, behavioural and motor difficulties in the Sanfilippo syndrome: An epidemiological study. Journal of Mental Deficiency Research 1983; 27: 185–203
  • Robertson S. P., Klug G. L., Rogers J. G. Cerebrospinal fluid shunts in the management of behavioural problems in Sanfilippo syndrome (MPS III). European Journal of Pediatrics 1998; 157: 653–655
  • Ruijter G. J. G., Valstar M. J., van de Kamp J. M., van der Helm R. M., Durand S., van Diggelen O. P., et al. Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands. Molecular Genetics and Metabolism 2008; 93: 104–111
  • Schooler N., Rabinowitz J., Davidson M., Emsley R., Harvey P. D., Kopala L., et al. Risperidone and haloperidol in first-episode psychosis: A long-term randomized trial. American Journal of Psychiatry 2005; 162: 947–953
  • Scott H. S., Blanch L., Guo X.-H., Freeman C., Orsborn A., Baker E., et al. Cloning of the sulphamidase gene and identification of mutations in Sanfilippo A syndrome. Nature Genetics 1995; 11: 465–467
  • Tran P. V., Dellva M. A., Tollefson G. D., Beasley C. M., Jr, Potvin J. H., Kiesler G. M. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. Journal of Clinical Psychiatry 1997; 58: 205–211
  • Valstar M. J., Ruijter G. J. G., van Diggelen O. P., Poorthuis B. J., Wijburg F. A. Sanfilippo syndrome: A mini-review. Journal of Inherited Metabolic Disease 2008; 31: 240–252
  • Zhao H. G., Li H. H., Bach G., Schmidtchen A., Neufeld E. F. The molecular basis of Sanfilippo syndrome type B. Proceedings of the National Academy of Sciences of the United States of America 1996; 93: 6101–6105

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.